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Abstract
Hepatitis C (HCV) and HIV have common modes of transmission but information about HCV 
transmission risk, prevention, and treatment among persons with coinfection is lacking. The 
Medical Monitoring Project produces nationally representative estimates describing adults with 
diagnosed HIV in the United States. Using medical record data recorded during 6/2013–5/2017, 
we identified persons with detectable HCV RNA documented during the past 24 months. Among 
persons with coinfection, we described HCV transmission risk factors and receipt of HCV 
prevention services during the past 12 months and prescription of HCV treatment during the past 
24 months. Overall, 4.9% had documented active HCV coinfection, among whom 30.2% were 
men who have sex with men (MSM), 6.7% reported injection drug use, and 62.1% were prescribed 
HCV treatment. Among MSM, 45.5% reported condomless anal sex and 45.5% received free 
condoms. Among persons who used drugs, 30.8% received drug or alcohol counseling, and among 
persons who injected drugs, 79.2% received sterile syringes. Among persons with HIV/HCV 
coinfection, recent drug injection was uncommon and most received sterile syringes. However, 1 
in 3 were MSM, of whom half reported recent HCV sexual transmission risk behaviors. More than 
one-third of those with coinfection were not prescribed curative HCV treatment.
Keywords
Coinfection; direct acting antiviral; hepatitis C; HIV; prevention
In the United States, hepatitis C virus (HCV) infection is a leading cause of liver-related 
morbidity and mortality, and co-infection with HCV and HIV increases risk for accelerated 
liver fibrosis, non-hepatic organ dysfunction, and overall mortality (Ly et. al, 2014). In the 
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past, interferon-based HCV treatments were used infrequently because of side effects and 
modest efficacy (Conteduca V, Sansonno D, Russi S, Pavone F, Dammacco F, 2014). Despite 
the greater risk of HCV-associated morbidity and mortality in persons with HIV/HCV 
coinfection, uptake of interferon-based HCV treatments was lower among HIV/HCV 
coinfected compared with the HCV monoinfected persons (Thomas, 2008, Vellozzi, 2011). 
Starting in 2011, the development of a new class of HCV medications—direct acting 
antivirals (DAA)—marked the beginning of a new era in HCV therapeutics (Conteduca, 
2014). In clinical practice since early 2014, safe, tolerable, interferon-sparing DAA 
treatment regimens have made HCV cure possible for 92–97% of persons with HIV/HCV 
coinfection and have resulted in a shift in clinical and public health efforts related to the 
prevention, control, and clinical management of HCV and HCV elimination goals proposed 
for the United States (2014; American Association for the Study of Liver Disease-Infectious 
Disease Society of America 2018; Wyles, 2015; Naggie, 2015; Sulkowski, 2014).
HCV in the United States affects persons born from 1945–1965 disproportionately (Smith, 
2012; Hofmeister, 2018; Centers for Disease Control and Prevention, 2018a). However, with 
aging of the US population (US Census Bureau, 2017), deaths in this birth cohort due to 
HCV-related and other causes may lower the overall prevalence of HCV (Hofmeister, 2018). 
Concurrently, the incidence of HCV infections has increased among young people who 
inject drugs (PWID) and among HIV-infected gay, bisexual, and other men who have sex 
with men (collectively referred to as MSM) (Suryaprasad, 2014; Zibbel, 2015; Hagan, 
Jordan, Neurer, Cleland, 2015; Fierer, 2011; Kaplan-Lewis & Dierer, 2015). The Centers for 
Disease Control and Prevention (CDC) recommends HCV testing of persons with HIV 
infection (PWHIV), persons with HCV transmission risk factors, such as current or past 
injection drug use, and persons born from 1945–1965 regardless of risk factor (Alter, 1998). 
Additionally, individuals should be tested for HCV before receiving HIV pre-exposure 
prophylaxis (PrEP) (United States Public Health Service, 2017). Although new HIV 
diagnoses have decreased nationally from 2011–2016 due at least in part to improvements in 
access to HIV care and treatment including biomedical prevention strategies such as 
antiretroviral treatment as prevention and PrEP (Centers for Disease Control and Prevention 
2016b), these interventions may be insufficient to reduce transmission of HCV resulting 
from ongoing behavioral risk among persons with HIV/HCV coinfection and limited access 
to HCV treatment. Information about the prevalence of behavioral risk factors for HCV 
transmission, receipt of prevention services, and prescription of HCV treatment among 
persons with HIV/HCV coinfection is very limited. To address this knowledge gap and to 
inform the development of successful interventions to prevent HCV transmission and reduce 
HCV-associated morbidity and mortality among PWHIV, we analyzed data from the 
Medical Monitoring Project (MMP) describing these factors among persons with HIV/HCV 
coinfection, To better understand persons who may be at highest risk for forward 
transmission of HCV, we also measured behavioral risk factors among persons not 
prescribed HCV treatment. Finally, to inform efforts to promote health equity, we assessed 
possible sociodemographic disparities in prescription of hepatitis C treatment.
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Methods
MMP is an annual cross-sectional survey designed to produce nationally representative 
estimates of behavioral and clinical characteristics of adults with diagnosed HIV in the 
United States. MMP data collection is a part of routine public health surveillance, and was 
thus determined to be nonresearch (Centers for Disease Control and Prevention 2010c). 
Participating states or territories obtained local institutional review board approval to collect 
data, when required. Informed consent was obtained from all participants.
Sample Design
Briefly, MMP used a two-stage sampling method, in which during the first stage, 16 states 
and Puerto Rico were sampled from all states, the District of Columbia, and Puerto Rico. 
During the second stage, simple random samples of persons with diagnosed HIV aged 18 
years and older and alive as of December 31st of the previous year were drawn for each 
participating state/territory from the National HIV Surveillance System (Centers for Disease 
Control and Prevention, 2018d), a census of persons with diagnosed HIV in the United 
States. All sampled states and 1 territory participated in MMP, and included California 
(including the separately funded jurisdictions of Los Angeles County and San Francisco), 
Delaware, Florida, Georgia, Illinois (including Chicago), Indiana, Michigan, Mississippi, 
New Jersey, New York (including New York City), North Carolina, Oregon, Pennsylvania 
(including Philadelphia), Puerto Rico, Texas (including Houston), Virginia, and Washington. 
Data were weighted based on known probabilities of selection at state or territory and person 
levels (American Association for Public Opinion Research 2011). In addition, data were 
weighted to adjust for person nonresponse and post-stratified to National HIV Surveillance 
System population totals (Harringa & West, 2010).
Data Collection
Data were collected via phone or face-to-face interviews and medical record abstractions. 
For the 2015 cycle, interviews were conducted during June 2015-May 2016. For the 2016 
cycle, interviews were conducted during June 2016-May 2017. Clinical data recorded in 
medical records during 24 months prior to the interview were collected. We pooled data 
from the 2015 and 2016 data collection cycles for this analysis, which included data 
recorded in medical records during June 2013–May 2017. Response rates for adults with 
diagnosed HIV were 39.8% for the 2015 cycle and 44.3% for the 2016 cycle.
Measures
Transmission risk factors, such as condomless anal sex, non-injection and injection drug use, 
and alcohol and drug use before or during sex, were assessed with validated interview 
questions (Centers for Disease Control and Prevention 2019e). Description of alcohol use 
was based on responses to interview questions about the number of days in the past month 
during which women consumed more than 4 units or men consumed more than 5 units of 
alcohol in one sitting. Drug use was described based on responses to interview questions 
about the frequency of use of specific injection and noninjection drugs during the past 12 
months. Respondents also indicated whether they drank alcohol or used injection or non-
injection drugs before or during sex in the past 12 months. Active HCV infection was 
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defined as having a positive test for viremia (qualitative or quantitative HCV RNA PCR 
assay result) recorded in the medical record. HCV RNA levels were categorized as < or ≥6 
million copies/mL which is a predictor of relapse following treatment with DAAs (American 
Association for the Study of Liver Disease-Infectious Disease Society of America 2018). 
Most recent HIV RNA levels were categorized as undetectable or <200 copies/mL vs. ≥200 
copies/mL based on the ability of these cut-offs to predict subsequent virologic failure 
(Panel on Antiretroviral Guidelines for Adults and Adolescents, 2019). CD4 counts were 
categorized as 0–199, 200–499, and ≥500 cells/μL based on CDC disease stage classification 
(Centers for Disease Control and Prevention HIV Surveillance Report, 2017). For the 
assessment of severity of liver disease, laboratory data recorded in the medical record, 
including platelets, alanine aminotransferase (ALT), and aspartate aminotransferase (AST), 
were used to calculate Fibrosis-4 (FIB-4) and serum AST-to-platelet ratio index (APRI) 
scores with cut-offs developed to predict significant fibrosis and cirrhosis in patients with 
HIV/HCV coinfection (Sterling, 2006; Wai, 2003). Prescription of HCV treatment was 
defined as documentation of prescription of any approved HCV antiviral agent.
Analytic Methods
The analytic dataset included 415 records of persons with medical record documentation of 
detectable HCV RNA in the past 24 months among 7692 records in the full dataset. Those 
with an undetectable HCV RNA or no available HCV RNA result were excluded from the 
analytic population. We computed frequencies, weighted percentages, and 95% confidence 
intervals (CI) to estimate the prevalence of sociodemographic and clinical characteristics, 
behavioral risk factors for HCV transmission and receipt of prevention services during the 
preceding 12 months, and prescription of HCV treatment in the previous 24 months. The 
Rao-Scott chi-square was used to assess associations between clinical and sociodemographic 
characteristics of persons with HIV/HCV coinfection and prescription of any HCV treatment 
in the past 24 months. All comparisons were 2-sided and P <.05 was considered significant. 
Data were not reported for estimates with a coefficient of variation ≥30%. All analyses 
accounted for complex sample design and unequal selection probabilities, and were 
conducted using SAS and SAS-callable SUDAAN.
Results
An estimated 4.9% (CI 4.4–5.4) of adults with diagnosed HIV had documented active HCV 
infection during the past 24 months (data not displayed on a table). An estimated 80.2% of 
persons with HIV/HCV coinfection were male (Table 1), 71.6% were born from 1945–1965, 
45.2% were black/African American non-Hispanic, 41.9% had education beyond high 
school, 44.9% were men who had sex with women only, and 30.2% were MSM. An 
estimated 75.0% had public insurance only, 60.3% were living below the federal poverty 
level, 11.8% reported having been homeless in the past 12 months, and 8.2% reported 
having been incarcerated in the past 12 months. Most (92.4%), had been prescribed 
antiretroviral treatment, 80.7% had an HIV viral load that was undetectable or <200 
copies/mL at last testing, and 52.6% had a mean CD4+ T-lymphocyte cell (CD4) count ≥500 
cells/mm3 in the past 12 months. There was evidence of advanced liver fibrosis/cirrhosis in 
14.1% who had a FIB-4 score of >3.25 and 10.5% who had an APRI score >1.5.
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Overall, 27.0% of persons with HIV/HCV coinfection reported engaging in condomless anal 
or vaginal sex in the past 12 months (Table 2). Among MSM with coinfection, 45.5% 
reported condomless anal sex in the past 12 months. Regarding substance use, an estimated 
17.5% reported drinking alcohol before or during sex, 10.2% reported binge drinking 
alcohol (defined as men who drank ≥5 or women who drank ≥4 alcoholic beverages on a 
single occasion) in the past 30 days, 30.1% reported non-injection drug use, 30.5% reported 
non-injection drug use before or during sex, 6.7% reported injection drug use, and 6.4% 
reported injection drug use before or during sex in the past 12 months.
An estimated 73.1% of persons with HIV/HCV coinfection reported receiving at least one 
prevention service in the past 12 months designed to protect themselves and their partners 
from HIV and sexually transmitted infections, including receiving informational materials, 
or having a conversation with an outreach worker, counselor, or prevention worker, with a 
doctor, nurse, or other healthcare worker, or in an organized small group (Table 3). Among 
those reporting any anal or vaginal sex, 67.0% reported receiving free condoms in the past 
12 months. Among MSM, 42.3% reported receiving free condoms in the past 12 months. 
Among those reporting injection or non-injection drug use, an estimated 30.8% reported 
receiving drug or alcohol counseling in the past 12 months. Among PWID, 79.2% received 
sterile syringes from a needle exchange, pharmacy, or health care facility.
HCV treatment was prescribed during the past 24 months for an estimated 62.1% of persons 
with HIV/HCV coinfection (Table 4). Prescription of HCV treatment was associated with 
being prescribed HIV antiretroviral therapy in the past 12 months, having less advanced liver 
fibrosis, and not using non-injection drugs before or during sex (Supplementary Tables 1, 2). 
Prescription of HCV treatment was not associated with being born during 1945–1965, race/
ethnicity, gender, education, type of health insurance, reported incarceration or 
homelessness, sexual transmission risk behaviors, or receipt of prevention services 
(Supplementary Tables 1–3).
Discussion
An estimated 4.9% of PWHIV had recent medical record documentation of active HCV 
coinfection. We found substantial missed opportunities in this population to prevent HCV 
transmission, decrease HCV-related morbidity, and reduce health disparities. Ending HCV 
will require effective interventions to address substance use disorders, reduce sexual 
transmission risk behaviors among MSM, and remove barriers to HCV treatment for persons 
with HIV/HCV coinfection.
Our estimate that nearly 5% of PWHIV had documented active HCV infection in the past 24 
months compares with 1% of non-institutionalized US civilians as reported by The National 
Health and Nutrition Survey (NHANES) between 2013 and 2016 (Hofmeister, 2018). 
NHANES did not report estimates of HIV/HCV coinfection during this time period. 
Previous information about HCV infection among PWHIV in the United States is limited. In 
2009, an estimated 21% of HIV patients who were tested for past or present HCV infection 
tested positive (Garg, Brooks, Luo, Skarbinski, 2014). However, prevalence varies widely by 
subgroup: 1–12% among MSM, 9–27% among heterosexuals, and 72–95% among PWID 
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(Alter, 2006). HIV cohort studies have reported HCV viremia among approximately 12% of 
cohort members (Cacahy, 2014; Vellozzi, 2011). Several factors could explain why our 
estimate of active HCV coinfection is lower than these earlier reports. First, our data 
describe HCV viremia in the era of DAAs, during which some persons with coinfection 
would presumably have been cured prior to our 2-year observation period. HIV cohort data 
were obtained prior to or early after the introduction of DAAs. Second, we recorded HCV 
lab data from the most recent 2-year period. HIV cohorts recorded viremia at any time since 
cohort enrollment. Third, previous studies may have included a higher percentage of PWID.
There are similarities in the sociodemographic characteristics of the HIV/HCV coinfected 
population and the overall HCV-infected population in the United States. We estimated that 
persons born from 1945–1965 accounted for 72% of persons with coinfection, which is 
comparable to previous estimates among all persons with HCV-infection in the United States 
(Smith, 2012; Hofmeister, 2018). Males accounted for 80% of persons with coinfection 
compared with 64% of all persons with HCV infection. However, compared with persons 
with HCV overall, double the percentages of persons with coinfection were living in poverty 
(60% vs. 29%) and were black (45% vs. 25%) (Hofmeister, 2018). The increased risk of 
poor outcomes among persons with coinfection compared with HCV monoinfected persons, 
including end-stage liver disease, hepatocellular carcinoma, and death (Rein et al 2011), 
compounds the burden of these income and racial disparities. To reduce the risk of morbidity 
and mortality from these complications and to reduce health disparities, access to curative 
treatment for persons with coinfection is urgently needed.
Injection drug use remains the leading cause of HCV transmission and the incidence of 
acute HCV infection among young PWID has been increasing since the mid-2000s, 
especially in nonurban settings including Appalachia (Suryaprasad, 2014; Zibebell, 2015). 
However, we found that only 1 in 13 persons with HIV reported injection drug use in the 
past 12 months and, although our relatively small sample size did not permit us to generate a 
stable estimate of the percentage of PWID who shared needles or other injecting equipment, 
79% of those who injected reported receiving sterile syringes. Although we did not ascertain 
the percentage that used drugs intranasally, this route of drug use is considered a risk factor 
for HCV transmission and warrants HCV screening per United States Preventative Services 
Task Force recommendations (Moyer, 2013). We found that among persons with HIV/HCV 
coinfection, 31% reported non-injection drug use in the past 12 months. Receipt of 
substance use counseling among persons who used drugs was low. Given the increasing 
number of reported acute HCV cases among PWID (Suryaprasad, 2014; Zibebell, 2015), 
access to substance use services and sterile injecting equipment for all PWID is vital.
Although sexual transmission of HCV is generally inefficient (Terrault, 2013), sexual 
transmission among MSM with HIV has been identified as an emerging challenge for HCV 
prevention (Suryaprasad, 2014; Zibbell, 2015; Hagan, 2015; Fierer, 2011; Kaplan-Lewis & 
Fierer, 2015). Two US studies have reported an HCV incidence rate of 0.21–0.51 per 100 
person-years among MSM with HIV (Witt, 2013; Taylor, 2011). Factors associated with 
incident HCV infection in this population include condomless anal intercourse, antecedent 
syphilis, gonorrhea, or chlamydial infection, history of injection drug use, having sex with 
concurrent methamphetamine use, and douching prior to anal intercourse (Fierer, 2011; Witt, 
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2013; Apers, 2015). We found that among MSM with HIV/HCV coinfection, an estimated 
46% reported engaging in condomless anal sex in the past 12 months. A case-control study 
in New York City found that condomless insertive and receptive anal sex increase the odds 
of becoming HCV-infected 8-fold and 25-fold, respectively among HIV-positive MSM 
(Fierer, 2011). The high prevalence of condomless anal sex among MSM with HIV 
underscores the importance of testing this population for HCV and counseling MSM with 
HIV/HCV coinfection about sexual risk reduction to prevent HCV transmission to their 
partners. Providers must explain to HIV patients that highly effective biomedical strategies 
for reducing HIV transmission, including HIV treatment as prevention and PrEP, have no 
biologic activity against HCV and cannot be relied upon to prevent HCV transmission.
Despite widely disseminated recommendations to treat persons with HIV/HCV coinfection 
for HCV (American Association for the Study of Liver Disease-Infectious Disease Society 
of America 2018), more than one-third were not prescribed HCV treatment during the 
period following the introduction of DAAs. We found that a higher percentage of untreated 
persons reported risky drug use suggesting that providers may be deferring treating patients 
with active drug use or that Medicaid sobriety requirements in some states may be a barrier 
to prescribing treatment (Canary, Klevens, Holmberg, 2015; Barua, Greenwald, Grebely, 
Dore, Swan, Taylor, 2015), Despite treatment eligibility requirements of some payers that 
patients must have more advanced liver fibrosis, treated patients had lower fibrosis scores 
suggesting that patients with more advanced fibrosis may be less likely to receive treatment. 
Although HCV monoinfected patients face Medicaid restrictions and cumbersome pre-
authorization requirements limiting access to treatment in some states, we did not find 
differences in prescription of HCV treatment for coinfected persons based on insurance type. 
Further research is needed to identify health system factors that could explain why some 
patients are treated and others are not, including facility type, availability of onsite 
supportive services designed to increase care engagement, and the use of decision support 
including clinical reminders in electronic health records.
Although nearly all persons with HIV/HCV coinfection can be cured with DAAs (Wyles, 
2015; Naggie, 2015), reinfection rates are high. Incidence of reinfection of MSM with HIV 
ranges from 2.9–15.2 per 100 persons-years and 2-year cumulative rates of reinfection 
ranging from 25–33% (Ingiliz, 2016; Lambers, 201; Chaillon, 2017) Incidence of reinfection 
of PWID ranges from 0–5.3 per 100 person-years for those following completion of 
interferon-based treatment to as high as 28.8 per 100 person-years among a prospective 
cohort of active users (Grady, Schinkel, Thomas, Dalgard, 2013, Weir, 2016; Midgard, 2016, 
Aspinall, 2013; Sacks-Davis, 2013). The high reinfection risk among persons with 
HIV/HCV coinfection highlights the challenges of applying a treatment as prevention 
strategy for HCV without concurrently addressing ongoing sexual and drug use risk 
behaviors. Theoretical models suggest that scaling up treatment with DAAs for PWID 
coupled with opioid substitution therapy and access to needle and syringe services could 
reduce HCV transmission and achieve reductions in prevalence of >50% over 10 years 
(Martin, Hickman, Hutchinson, Goldberg, Vickerman, 2013; Hickman, De Angelis, 
Vickerman, Hutchinson, Martin, 2015; Hellard, 2015).
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Our analysis is subject to the following limitations. First, our definition of HCV coinfection 
as documentation of detectable RNA during the study period allowed us to conservatively 
estimate active HCV coinfection among persons who were tested during the study period, 
but did not capture persons with coinfection who did not have an HCV RNA test during that 
period. Also, because of uncertainty about the HCV status of persons not tested for HCV 
RNA during the study period, we were unable to confidently classify persons as HIV 
monoinfected for comparison with coinfected persons across sociodemographic 
characteristics and risk behaviors. Second, we were unable to evaluate the temporality of 
HIV and HCV infections or identify incident HCV infection because of the cross-sectional 
design of MMP. Third, since we lack longitudinal data on respondents, we were unable to 
evaluate treatment outcomes, or cases of possible reinfection in this population. Fourth, we 
were unable to evaluate the infection status and risk behaviors of the sexual or drug using 
partners of our population. Fifth, since data collected on risk behaviors relied on interview 
questions, reported risk behaviors may be underestimated due to socially desirable 
responding. Finally, our sampling and weighting design did not allow geographic 
comparisons.
Conclusions
Recent injection drug use is relatively uncommon among persons with coinfection and most 
who injected received sterile syringes. However, nearly half of MSM with coinfection 
reported sexual behaviors placing their partners at high risk of acquiring HCV. Despite 
recommendations to treat all persons with HCV, over one-third of persons with HIV/HCV 
coinfection were not prescribed curative HCV treatment. Health care providers should 
evaluate persons with HIV/HCV coinfection for transmission risk behaviors, link them to 
appropriate prevention services to reduce HCV transmission, and prescribe treatment for 
HCV. Improving access to HCV prevention services and treatment for persons with 
HIV/HCV coinfection is essential for achieving HCV elimination goals and reducing health 
disparities.
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Table 1.
Sociodemographic and Clinical Characteristics of Persons with HIV/Hepatitis C Coinfection in the United 
States, Medical Monitoring Project, June 2013–May 2017. N=415
No. Weighted Column % (95% CI)
Gender
 Male 318 80.2 (76.0–84.4)
 Female 89 19.8 (15.6–24.0)
Born 1945–1965
 No 124 28.4 (23.3–33.5)
 Yes 291 71.6 (66.5–76.7)
Race/Ethnicitya
 White, non-Hispanic 111 27.1 (18.1–36.1)
 Black, non-Hispanic 189 45.2 (34.8–55.7)
 Hispanic or Latino 91 21.4 (13.0–29.8)
 Other 24 6.3 (3.1–9.6)
Age (years)
 18–39 31 8.2 (5.2–11.1)
 40–49 85 18.8 (14.8–22.9)
 50–59 179 42.5 (36.5–48.5)
 ≥60 120 30.5 (25.6–35.3)
Education
 <High School 122 29.2 (22.8–35.6)
 High School diploma or equivalent 121 28.9 (23.8–34.0)
 >High School 171 41.9 (35.6–48.2)
Sexual behavior/orientationb
 MSW only 177 44.9 (39.3–50.5)
 Any MSM 135 30.2 (24.9–35.6)
 Any WSM 86 18.8 (14.8–22.7)
 Other 17 6.1 (1.6–10.6)
Health Insurance
 Any private insurance 76 17.3 (13.6–21.0)
 Public insurance only 311 75.0 (69.1–80.8)
 RWc only/Uninsured/Unspecified 28 7.7 (3.6–11.8)
At or below the federal poverty level (FPL) in the past 12 months
 <100% FPL 240 60.3 (55.1–65.6)
 ≥100% - <139% FPL 35 8.3 (5.7–10.9)
 ≥139% - <400% FPL 94 25.0 (19.6–30.4)
 ≥400% FPL 28 6.4 (3.8–9.0)
Homelessd in the past 12 months
 No 367 88.2 (83.9–92.5)
 Yes 48 11.8 (7.5–16.1)
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No. Weighted Column % (95% CI)
Incarcerated in the past 12 months
 No 384 91.8 (88.4–95.2)
 Yes 31 8.2 (4.8–11.6)
Major depression in the past 12 months
 No depression 300 71.9 (67.6–76.1)
 Other depression 62 16.7 (11.6–21.7)
 Major depression 46 11.5 (7.7–15.3)
Prescribed ART in the past 12 months
 No or Missing/Unknown 27 7.6 (4.5–10.8)
 Yes 388 92.4 (89.2–95.5)
Most recent HIV viral load undetectable or less than 200 copies/mL
 HIV viral load undetectable or <200 copies/ml 339 80.7 (75.9–85.5)
 HIV viral load detectable, ≥200 copies/ml or Missing/unknown 76 19.3 (14.5–24.1)
Mean CD4 count in the past 12 months
 0–199 57 16.2 (11.2–21.2)
 200–499 129 31.2 (25.1–37.2)
 ≥500 205 52.6 (44.9–60.4)
HCV quantitative viral load in the past 12 months
 <6 million international units/mL 213 82.6 (78.1–87.0)
 ≥6 million international units/mL 46 17.4 (13.0–21.9)
FIB-4 scoree
 ≤ 1.45 152 40.9 (35.1–46.7)
 1.45–3.25 184 45.1 (40.1–50.1)
 > 3.25 58 14.1 (10.2–17.9)
APRI scoref
 ≤ 0.5 218 55.4 (49.4–61.3)
 0.5–1.5 134 34.1 (28.7–39.6)
 > 1.5 42 10.5 (6.9–14.0)
Abbreviations: No., sample size; CI, confidence interval; MSM, men who have sex with men; MSW, men who have sex with women; WSM, 
women who have sex with men; ART, antiretroviral therapy; HCV, hepatitis C virus; FIB-4, Fibrosis-4; APRI, serum AST-to-platelet ratio index
a.Categories are mutually exclusive. Hispanics or Latinos could be of any race.
b.Sexual transmission risk or potential risk based on reported sexual behavior and sexual orientation
c.
Ryan White HIV/AIDS Program, AIDS Drug Assistance Program
d.
Defined as having lived on the street, in a shelter, in a single room occupancy hotel or in a car
e.
FIB-4 score calculated as Age(years) × AST(U/L)/(Platelets(109/L) × sqrt (ALT(U/L))
f.APRI score calculated as (AST(U/L)/40) / Platelets(109/L) × 100
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Table 2.
Prevalence of Sexual and Substance Use Behaviors in the Past 12 Months Among Persons With HIV/HCV 
Coinfection in the United States, Medical Monitoring Project, June 2013–May 2017. N=415
Risk behavior No. Weighted Column % (95% CI)a
Sexual risk behaviors
 Any condomless anal or vaginal sexa
  No 299 73.0 (67.0–79.0)
  Yes 109 27.0 (21.0–33.0)
 Any condomless anal sex among MSMb
  No 72 54.5 (43.8–65.2)
  Yes 63 45.5 (34.8–56.2)
Substance use risk behaviors
 Drank alcohol before or during sexa
  No 330 82.4 (77.7–87.0)
  Yes 75 17.6 (13.0–22.3)
 Binge drank in past 30 daysc
  No 363 89.8 (85.5–94.1)
  Yes 42 10.2 (5.9–14.5)
 Any non-injection drug use
  No 288 69.9 (62.7–77.0)
  Yes 119 30.1 (23.0–37.3)
 Use of non-injection drugs before or during sexa
  No 339 83.4 (77.5–89.3)
  Yes 69 16.6 (10.7–22.5)
 Any injection drug use
  No 370 93.3 (91.0–95.6)
  Yes 37 6.7 (4.4–9.0)
 Injection drug use before or during sexa
  No 287 96.6 (94.9–98.3)
  Yes 20 3.4 (1.7–5.1)
Abbreviations: No., sample size; CI, confidence interval; MSM, men who have sex with men
a.
The denominator is persons with HIV/HCV coinfection (N=415). Missing data for this variable were excluded for calculation.
b.Of the 415 HIV/HCV coinfected individuals, 135 respondents were men who had sex with men in the past 12 months or who described 
themselves as gay or bisexual, which is the denominator for this variable. Missing data for this variable were excluded for calculation.
c.
Defined as consumptions of ≥5 alcoholic beverages for men or ≥4 alcoholic beverages for women in a single occasion
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Table 3.
Prevention Services Received in the Past 12 Months by Persons With HIV/HCV Coinfection in the United 
States, Medical Monitoring Project, June 2013–May 2017. N=415
Prevention Service No. Weighted % (95% CI)
Prevention Service Designed to Protect Oneself and Others from HIV/STDs
 Received informational materials 254 58.0 (51.4–64.7)
 Conversation with outreach worker, counselor or prevention worker 149 33.3 (27.5–39.1)
 Conversation with doctor, nurse, or healthcare worker 237 56.7 (51.4–62.0)
 Participated in organized small group 87 20.5 (16.0–25.0)
 Any of the above prevention services 314 73.1 (67.3–78.8)
Received free condoms (all sexually active persons)a 148 67.0 (60.2–73.8)
Received free condoms (MSM)b 56 42.3 (32.3–52.3)
Drug or alcohol counselingc 42 30.8 (21.2–40.3)
Received sterile syringesd 32 79.2 (62.2–96.3)
Abbreviations: No., sample size; CI, confidence interval; STD, sexually transmitted disease: MSM, Men who have sex with men
a.
The denominator is persons reporting any anal or vaginal sex in the past 12 months (N = 223)
b.
The denominator is men who had sex with men in the past 12 months or who described themselves as gay or bisexual (N = 135)
c.
The denominator is limited to those reporting any injection or non-injection drug use in the past 12 months (N = 133)
d.
The denominator is persons who reported injecting drugs in the past 12 months (N = 37). Syringes were received at a needle exchange, pharmacy, 
or health care facility.
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Table 4.
HCV Treatment Prescribed in the Past 24 Months for Adults With HIV/HCV Coinfection in the United States, 
Medical Monitoring Project, June 2011–May 2015. N=415
HCV Treatmenta No. Weighted % (95% CI)
Any treatment regimen 257 62.1 (56.9–67.3)
 DAA regimen onlyb 226 55.8 (50.4–61.1)
 DAAb and ribavirin 21 4.0 (2.0–6.1)
 Other regimen
No treatment 151 37.9 (32.7–43.1)
Abbreviations: No., sample size; CI, confidence interval; DAA, direct acting Antiviral
a.
The coefficient of variation for the weighted estimate of persons prescribed interferon regimens was >.3 and therefore the estimate was unstable 
and is not reported.
b.
DAAs include: ledipasvir/sofosbuvir (Trade name: Harvoni), paritaprevir/ritonavir/ombistavir/dasabuvir (Trade name: Viekera Pak or Technivie 
(combination excluding dasabuvir)), simeprevir/sofosbuvir (Trade name: olysio/sovaldi), daclatasvir/sofosbuvir (Trade name: Daklinza/sofosbuvir), 
simeprevir (Trade name: Olysio), telaprevir (Trade name: Victrelis), boceprevir (Trade name: Incivek), elbasvir/grazoprevir (Trade name: Zepatier), 
Glecaprevir/pibrentavir (Mavyret), Sofosbuvir/velpatasvir (Trade Name: Epclusa), Sofosbuvir/velpatasvir/voxilaprevir (Trade Name: Vosevi)
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